U.S., April 21 -- ClinicalTrials.gov registry received information related to the study (NCT07538583) titled 'Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome' on March 24.
Brief Summary: This is a multicenter, open-label study to evaluate the safety, tolerability, and efficacy of 4% QRX003 lotion applied twice daily (BID) for 12 weeks to Netherton syndrome (NS) diseased skin in all affected areas of the body excluding the scalp (the Treatment Area), totaling approximately 50% Body Surface Area (BSA) or more.
Study Start Date: March 19
Study Type: INTERVENTIONAL
Condition:
Netherton Syndrome
Intervention:
DRUG: QRX003
Serine Protease Inhibitor
Recruitment Status: RECRUITING
Sponsor: Quoin Pharmaceutica...